Yourgene® Insight DPYD – IVDR Certified Assay Just launched!
Confidence in Every Treatment Decision
Go beyond standard DPYD testing with Insight – We are proud to launch the newest version of our DPYD genotyping kit which is IVDR certified that incorporates the latest global guideline recommendations of expanded variant coverage.
More Insight, smarter dosing, safer patients.
Read the press release here.
The Yourgene® Insight DPYD kit uses fluorescent ARMS (Amplification Refractory Mutation System) allele specific amplification technology, which detects point mutations, insertions or deletions in DNA, to deliver accurate, rapid detection of 19 key DPYD variants with a fast turnaround time of only 4 hours! For a full list variants see the table below.
| Tier 1 | Tier 2 | Other DPYD Variants |
|---|---|---|
|
c.1905+1G>A
|
c.299_302del
|
c.496A>G
|
|
c.1679T>G
|
c.703C>T
|
c.2043_2058del
|
|
c.1129-5923C>G,
c.1236G>A |
c.1314T>G
|
c.2194G>A
|
|
c.557a>G
|
c.1475C>T
|
c.601A>C
|
|
c.868A>G
|
c.1774C>T
|
c.2872A>G
|
|
c.2279C>T
|
c.2639G>T
|
|
|
c.2846A>T
|
|
|
| Parameter | Details |
|---|---|
|
Format
|
Two-tube assay:
- Tube 1 detects the 19 defined variants - Tube 2 detects the corresponding wildtype sequence to detect heterozygotes - STR markers are included in each tube to aid sample identification |
|
PCR Method
|
ARMS-PCR
|
|
Hands on time
|
<60 mins
|
|
Total turnaround time
|
PCR: ~ 3 hours
Capillary Electrophoresis: ~ 1 hour |
|
Intended sample type
|
DNA extracted from whole human blood (EDTA preserved)
|
|
Instrumentation
|
Thermal Cycler & Capillary Electrophoresis Genetic Analysers. Developed on ABI 3500 and SeqStudio CE instruments
|
|
Software analysis
|
GeneMapper™ or GeneMarker®
|
Seraseq® DPYD DNA Mutation Mix
You can now buy reference material from us when purchasing Yourgene® Insight DPYD kits.
We stock the Seraseq® DPYD DNA Mutation Mix (RUO), which is compatible with the Yourgene® Insight DPYD Assay (RUO).
In this edition of Your Expert, Yourgene Health interviewed Dr. Daniel Hertz, Associate Professor at the University of Michigan College of Pharmacy, about the importance of DPYD testing, it’s role as a standard of care, and the ongoing challenges to broader clinical adoption.
Dr. Daniel Hertz is an Associate Professor at the University of Michigan College of Pharmacy. He received his PharmD from Rutgers University and PhD from the University of North Carolina under Dr. Howard McLeod. Dr. Hertz’s research focuses on developing individualized treatment strategies for patients with cancer and translating them into clinical practice. He has particular interests in biomarkers of taxane-induced neuropathy and DPYD testing to prevent severe fluoropyrimidine toxicity, aligning with his role as a Medical Advisor to Advocates for Universal DPD/DPYD Testing
(AUDT).
If you have a question or would like to learn more about our products and services, we're here to help.
